Epithalon (Epitalon): A Tetrapeptide Studied in Telomerase, Melatonin, and Aging Research

Research summary. Epithalon (also written Epitalon, Epithalone) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly, AEDG) developed in the 1980s by the laboratory of Vladimir Khavinson in Russia as a synthetic counterpart to a polypeptide pineal-gland extract called Epithalamin. It is one of the most extensively studied members of the Khavinson short-peptide bioregulator family, and the bioregulator most widely cited in the gerontology and telomere-biology literature.

Molecular profile

• Sequence: Ala-Glu-Asp-Gly (AEDG)
• Molecular formula: C₁₄H₂₂N₄O₉
• Molecular weight: ~390.4 g/mol
• PubChem CID: 219042
• CAS Number: 307297-39-8
• Class: Short peptide bioregulator (Khavinson peptides) — pineal/CNS tropism

Mechanism of action

Epithalon is reported to act through several proposed mechanisms, only some of which are independently confirmed in mainstream peptide biology:

• Telomerase activation. A widely cited line of work has reported that Epithalon induces telomerase activity in cultured human somatic cells and supports maintenance of telomere length in serially passaged cell lines [1].
• Modulation of melatonin synthesis. As a synthetic counterpart to the pineal extract Epithalamin, Epithalon has been reported to influence pineal melatonin production, with associated effects on AANAT and pCREB regulators of melatonin biosynthesis.
• Direct DNA / chromatin interaction. Within the broader bioregulator framework, Epithalon has been reported to bind specific gene promoter regions including those for CD5, IL-2, MMP2, Tram1, and AANAT, modulating downstream transcription.
• Antioxidant activity. Reductions in lipid peroxidation and oxidative-damage markers have been reported across multiple rodent models.

Preclinical research highlights

Lifespan extension. A frequently cited body of rodent work from the Anisimov and Khavinson laboratories has reported lifespan extensions ranging from approximately 10–25% with chronic Epithalon administration in mice and rats. Effects on tumour incidence have also been reported, with some studies showing reduced spontaneous tumour development in long-term treated animals [2].

Telomere biology in cell culture. In serially passaged human somatic cells, Epithalon exposure has been associated with elevated telomerase activity, extended population-doubling counts, and maintained telomere length compared with vehicle controls. The reported effect has not been independently replicated at scale outside the originating research group, which has been a point of methodological discussion in the broader telomere-biology literature.

Connective tissue and skin. Rodent dermal studies have reported increases in fibroblast activity (~30–45%) following Epithalon exposure, with associated increases in collagen, elastin, and MMP-2 expression.

Circadian and pineal function. Epithalon administration has been reported to restore pineal melatonin output in aged rodent models and to modulate PER1 gene expression, consistent with a role in circadian-rhythm regulation.

Retinal protection. A widely cited line of investigation in rat models of retinitis pigmentosa has reported preservation of retinal structure and bioelectric function in a high proportion of treated animals. These reports have generated continued interest in Epithalon as a research tool in retinal degeneration models.

Immune-system effects. Increased lymphocyte interferon-gamma expression has been reported, alongside modulation of other immune-cell-related parameters, consistent with the broader pleiotropic profile reported across the bioregulator family.

Limitations of the evidence base

As with other Khavinson bioregulators, several caveats apply:

• The supporting literature originates predominantly from a single research programme.
• The proposed direct chromatin-binding mechanism for an unmodified tetrapeptide remains controversial in mainstream peptide pharmacology.
• The reported telomerase activation is a high-profile claim that has not been robustly independently replicated.
• No registered Phase 2 or Phase 3 clinical trials of Epithalon appear in major Western trial registries at the time of writing.

Position within the bioregulator family

Epithalon is the most prominent member of the Khavinson programme by citation count, and it occupies a particular position in the family because of its association with pineal biology and telomere maintenance — both topics with broader resonance in mainstream gerontology. It is frequently studied in parallel with related short bioregulator peptides (Bronchogen, Cardiogen, Cortagen, Vesugen, Pinealon) but tends to be the entry point through which Western researchers first encounter the family.

Current research status

Epithalon remains an investigational research peptide. It is not approved as a therapeutic by any major regulatory authority. Its principal roles in current research include:

• A reference compound in geroprotective and telomere-biology research within the Khavinson framework
• A tool for studying short-peptide modulation of pineal melatonin biology
• A candidate molecule in retinal degeneration and age-related cellular senescence models

Key takeaways for researchers

• Epithalon is a tetrapeptide (Ala-Glu-Asp-Gly) synthetic counterpart to the pineal extract Epithalamin, developed in the Khavinson programme.
• Reported effects include telomerase activation in cultured cells, lifespan extension in rodents, and modulation of melatonin biosynthesis.
• It is the most widely cited member of the Khavinson short-peptide bioregulator family.
• Independent replication of key mechanistic claims (especially telomerase activation) remains limited.
• Epithalon is not an approved therapeutic.

References

1. Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;135(6):590–592.
2. Anisimov VN, Khavinson VK, Provinciali M, et al. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. International Journal of Cancer. 2002;101(1):7–10.

---

This article is provided for educational and research purposes only. Epithalon is a research peptide. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.